- Home
- BREA vs BRTX Comparison
BREA vs BRTX Comparison
Compare BREA & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- BRTX
- Stock Information
- Founded
- BREA 2022
- BRTX 1997
- Country
- BREA Ireland
- BRTX United States
- Employees
- BREA N/A
- BRTX N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- BRTX Managed Health Care
- Sector
- BREA Consumer Discretionary
- BRTX Health Care
- Exchange
- BREA Nasdaq
- BRTX Nasdaq
- Market Cap
- BREA 14.8M
- BRTX 12.5M
- IPO Year
- BREA 2023
- BRTX N/A
- Fundamental
- Price
- BREA $6.00
- BRTX $1.63
- Analyst Decision
- BREA
- BRTX
- Analyst Count
- BREA 0
- BRTX 0
- Target Price
- BREA N/A
- BRTX N/A
- AVG Volume (30 Days)
- BREA 5.4K
- BRTX 94.5K
- Earning Date
- BREA 01-01-0001
- BRTX 08-12-2025
- Dividend Yield
- BREA N/A
- BRTX N/A
- EPS Growth
- BREA N/A
- BRTX N/A
- EPS
- BREA N/A
- BRTX N/A
- Revenue
- BREA $2,988,009.00
- BRTX $605,200.00
- Revenue This Year
- BREA N/A
- BRTX $232.67
- Revenue Next Year
- BREA N/A
- BRTX $52.92
- P/E Ratio
- BREA N/A
- BRTX N/A
- Revenue Growth
- BREA 151.51
- BRTX 247.62
- 52 Week Low
- BREA $5.00
- BRTX $1.21
- 52 Week High
- BREA $19.50
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- BREA 42.63
- BRTX 52.74
- Support Level
- BREA $5.71
- BRTX $1.51
- Resistance Level
- BREA $6.56
- BRTX $1.89
- Average True Range (ATR)
- BREA 0.24
- BRTX 0.09
- MACD
- BREA -0.05
- BRTX 0.02
- Stochastic Oscillator
- BREA 27.37
- BRTX 38.10
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.